Option chain shows key data for GT Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for GT Biopharma.

GT Biopharma (NASDAQ:GTBP) Stock, Option Chain

GT Biopharma

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

cancer

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

GTBP

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

accounting-761599_1280

Offerings

Movers

GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules. 

What&#39;s Going On With GT Biopharma Stock Tuesday?

pharmaceutical

GT Biopharma shares are moving on heavy trading volume despite a lack of company-specific news. The stock is one of the top trending tickers on Stocktwits which may point to a rally led by retail traders. According to data from Benzinga Pro, more than 60.4 million shares have been traded in the session, far exceeding the stock&#39;s 100-day average of less than 11,000 shares.

What&#39;s Going On With GT Biopharma Stock?

GT Biopharma Inc

Press Releases

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

GT Biopharma Announces Exercise of Warrants

"Signal Advance, Inc. (OTC: SIGL) Achieves Technology Milestone with Revolutionary Next-Gen Signal Protection – More Stocks Inside"

GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

BNZI

CSDX

MBRX

SIGL

SKYX

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Equillium

Ernexa Therapeutics

iBio

Immuron Limited - American Depositary Shares

Immuron

Kairos Pharma

Leap Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Unity Biotechnology

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

GT Biopharma

GT Biopharma (GTBP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell